These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 228833)

  • 1. Peripheral neuropathy associated with cis-dichlorodiammineplatinum (II) treatment.
    Hadley D; Herr HW
    Cancer; 1979 Dec; 44(6):2026-8. PubMed ID: 228833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report.
    Kedar A; Cohen ME; Freeman AI
    Cancer Treat Rep; 1978 May; 62(5):819-21. PubMed ID: 207427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neuropathy and ophthalmologic toxicity after treatment with cis-dichlorodiaminoplatinum II.
    Becher R; Schütt P; Osieka R; Schmidt CG
    J Cancer Res Clin Oncol; 1980; 96(2):219-22. PubMed ID: 6248563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cis-dichlorodiammineplatinum(II) in advanced bladder cancer.
    Yagoda A; Watson RC; Gonzalez-Vitale JC; Grabstald H; Whitmore WF
    Cancer Treat Rep; 1976 Jul; 60(7):917-23. PubMed ID: 1009522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral sensory neuropathy and cisplatin chemotherapy.
    Roelofs RI; Hrushesky W; Rogin J; Rosenberg L
    Neurology; 1984 Jul; 34(7):934-8. PubMed ID: 6330613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral neuropathy and low dose cisplatin.
    Greenspan A; Treat J
    Am J Clin Oncol; 1988 Dec; 11(6):660-2. PubMed ID: 2847525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Neuropathy caused by cisplatin. 7 cases including one with an autopsy study].
    Amiel H; Gherardi R; Giroux C; Salama J; Bréau JL; Delaporte P
    Ann Med Interne (Paris); 1987; 138(2):96-100. PubMed ID: 3034113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral neuropathy after cis-platinum (II) (DDP) therapy.
    Reinstein L; Ostrow SS; Wiernik PH
    Arch Phys Med Rehabil; 1980 Jun; 61(6):280-2. PubMed ID: 6246848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.
    Cavaletti G; Marzorati L; Bogliun G; Colombo N; Marzola M; Pittelli MR; Tredici G
    Cancer; 1992 Jan; 69(1):203-7. PubMed ID: 1309303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Peripheral neuropathy caused by cisplatin in patients with lung cancer].
    Murata M; Yamaji Y; Futami H; Shimada Y; Fujita J; Hashimoto Y; Shiotani T; Irino S
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2283-8. PubMed ID: 2544151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.
    Ochs JJ; Freeman AI; Douglass HO; Higby DS; Mindell ER; Sinks LF
    Cancer Treat Rep; 1978 Feb; 62(2):239-45. PubMed ID: 346212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cis-Platinum-induced hypomagnesemia and peripheral neuropathy.
    Ashraf M; Scotchel PL; Krall JM; Flink EB
    Gynecol Oncol; 1983 Dec; 16(3):309-18. PubMed ID: 6317526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced bladder cancer: therapy with cis-dichlorodiammineplatinum(II), adriamycin, and 5-fluorouracil.
    Williams SD; Donohue JP; Einhorn LH
    Cancer Treat Rep; 1979; 63(9-10):1573-6. PubMed ID: 498156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of cis-dichlorodiammineplatinum(II) in cancer of the bilharzial bladder.
    Gad-el-Mawla N; Chevlen E; Hamza R; Ziegler JL
    Cancer Treat Rep; 1979; 63(9-10):1577-8. PubMed ID: 498157
    [No Abstract]   [Full Text] [Related]  

  • 15. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies.
    Chaudhry V; Rowinsky EK; Sartorius SE; Donehower RC; Cornblath DR
    Ann Neurol; 1994 Mar; 35(3):304-11. PubMed ID: 7907208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cis-dichlorodiammineplatinum(II) alone and combined with DTIC for treatment of disseminated malignant melanoma.
    Goodnight JE; Moseley HS; Eilber FR; Sarna G; Morton DL
    Cancer Treat Rep; 1979; 63(11-12):2005-7. PubMed ID: 393385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of cis-diamminedichloroplatinum(II) administered as a constant 5-day infusion.
    Lokich JJ
    Cancer Treat Rep; 1980; 64(8-9):905-8. PubMed ID: 6256073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. cis-Platinum combination chemotherapy of bladder cancer: an update.
    Williams SD; Einhorn LH; Donohue JP
    Cancer Clin Trials; 1979; 2(4):335-8. PubMed ID: 394869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complications of hypogastric artery cisplatin infusions.
    Menashe DS; Jacobs SC
    J Surg Oncol; 1989 Jul; 41(3):160-4. PubMed ID: 2545974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.